气道疾病患者对SARS-CoV-2感染的易感性。 - Suppr

Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.

作者信息

Conway Francesca M, Bloom Chloe I, Shah Pallav L

机构信息

Royal Brompton Hospital, London, United Kingdom.

Chelsea & Westminster Hospital, London, United Kingdom; and.

出版信息

Am J Respir Crit Care Med. 2022 Sep 15;206(6):696-703. doi: 10.1164/rccm.202111-2547PP.

DOI:10.1164/rccm.202111-2547PP

PMID:35549839

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9799128/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d21/9799128/e56cab09fdc2/rccm.202111-2547PPf1.jpg

相似文献

Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.

Am J Respir Crit Care Med. 2022 Sep 15;206(6):696-703. doi: 10.1164/rccm.202111-2547PP.

Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.

J Allergy Clin Immunol. 2020 Oct;146(4):790-798. doi: 10.1016/j.jaci.2020.08.008. Epub 2020 Aug 15.

Progression to a severe form of COVID-19 among patients with chronic respiratory diseases.

Respir Med Res. 2022 May;81:100880. doi: 10.1016/j.resmer.2021.100880. Epub 2021 Dec 30.

Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions.

Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):1-7. doi: 10.1097/ACI.0000000000000699.

Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression.

Eur Ann Allergy Clin Immunol. 2022 Nov;54(6):284-289. doi: 10.23822/EurAnnACI.1764-1489.233. Epub 2021 Sep 10.

The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society.

Respir Investig. 2021 Sep;59(5):679-682. doi: 10.1016/j.resinv.2021.06.008. Epub 2021 Jul 15.

SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.

J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.

Asthma Associated Cytokines Regulate the Expression of SARS-CoV-2 Receptor ACE2 in the Lung Tissue of Asthmatic Patients.

Front Immunol. 2022 Jan 17;12:796094. doi: 10.3389/fimmu.2021.796094. eCollection 2021.

[Asthma and COVID-19].

Rev Alerg Mex. 2022;69 Suppl 1:s15-s23. doi: 10.29262/ram.v69iSupl1.1009.

Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.

Med Hypotheses. 2020 Nov;144:110027. doi: 10.1016/j.mehy.2020.110027. Epub 2020 Jun 26.

引用本文的文献

Risk factors and effectiveness of vaccination for nosocomial SARS-CoV-2 acquisition throughout the SARS-CoV-2 pandemic.

BMC Infect Dis. 2025 Aug 19;25(1):1040. doi: 10.1186/s12879-025-11349-9.

Divergent responses to SARS-CoV-2 infection in bronchial epithelium with pre-existing respiratory diseases.

iScience. 2025 Feb 12;28(3):111999. doi: 10.1016/j.isci.2025.111999. eCollection 2025 Mar 21.

SARS-CoV-2 Lurking and Lingering in the Depths of Lungs.

Am J Respir Crit Care Med. 2024 Apr 1;209(7):779-780. doi: 10.1164/rccm.202401-0067ED.

Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.

Drug Saf. 2024 Feb;47(2):135-146. doi: 10.1007/s40264-023-01364-7. Epub 2023 Dec 12.

Disparities in outcomes of COVID-19 hospitalizations in native American individuals.

Front Public Health. 2023 Aug 15;11:1220582. doi: 10.3389/fpubh.2023.1220582. eCollection 2023.

Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.

Int J Med Sci. 2023 Apr 23;20(6):737-748. doi: 10.7150/ijms.78766. eCollection 2023.

Outcomes and risk factors with COVID-19 or influenza in hospitalized asthma patients.

Respir Res. 2022 Dec 13;23(1):342. doi: 10.1186/s12931-022-02265-6.

Recent developments in the immunopathology of COVID-19.

Allergy. 2023 Feb;78(2):369-388. doi: 10.1111/all.15593. Epub 2022 Dec 5.

COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics.

Drug Metab Dispos. 2023 Jan;51(1):130-141. doi: 10.1124/dmd.122.000934. Epub 2022 Oct 23.

Susceptibility of Patients with Asthma to a Poor Outcome of COVID-19.

Am J Respir Crit Care Med. 2022 Oct 1;206(7):922-923. doi: 10.1164/rccm.202205-0978LE.

本文引用的文献

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial.

BMJ. 2021 Nov 2;375:e068060. doi: 10.1136/bmj-2021-068060.

Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study.

Am J Respir Crit Care Med. 2022 Jan 1;205(1):36-45. doi: 10.1164/rccm.202107-1704OC.

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Lancet. 2021 Sep 4;398(10303):843-855. doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10.

Biologics may have a beneficial effect in asthma patients with COVID-19.

Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.01076-2021. Print 2021 Aug.

COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.

J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.

Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study.

Eur Respir J. 2021 Dec 9;58(6). doi: 10.1183/13993003.04474-2020. Print 2021 Dec.

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.

Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.

Lancet Respir Med. 2021 Aug;9(8):909-923. doi: 10.1016/S2213-2600(21)00095-3. Epub 2021 Apr 1.

Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial.

Eur Respir J. 2021 Jul 29;58(1). doi: 10.1183/13993003.00130-2021. Print 2021 Jul.

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.

Lancet Respir Med. 2021 Jul;9(7):699-711. doi: 10.1016/S2213-2600(21)00013-8. Epub 2021 Mar 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献